Merck previewed the top-line results of KEYNOTE-355 earlier, but oncologists now have the chance to look at the actual data, and try to make comparisons between the drug and as a first-line ...

Merck meanwhile will have to wait for further discussions with the FDA to determine whether it can tweak or supplement the data already filed for the drug, or will have to run another trial on a ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE: MRK) stands against other stocks that Jim Cramer discussed recently. On Wednesday, Jim Cramer, the host of Mad Money ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Pfizer's 7.5% dividend yield, strong R&D innovation, and defensive market position make it a smart buy. Read here for an ...

Behind declines for shares of Merck and Goldman Sachs, the Dow Jones Industrial Average is declining Wednesday morning. Supported by world-class markets data from Dow Jones and FactSet ...

Therefore Moneycontrol doesn't bear any responsibility for any trading losses you might incur as a result of using this data.

But if you've experienced identity theft or your personal identifiable information was compromised in a recent data breach, like the hacks of Change Healthcare or National Public Data, locking ...